Nova EYE Medical Ltd - Asset Resilience Ratio
Nova EYE Medical Ltd (EYE) has an Asset Resilience Ratio of 11.08% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Nova EYE Medical Ltd for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2001–2025)
This chart shows how Nova EYE Medical Ltd's Asset Resilience Ratio has changed over time. See EYE net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Nova EYE Medical Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Nova EYE Medical Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$2.62 Million | 11.08% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$2.62 Million | 11.08% |
Asset Resilience Insights
- Moderate Liquidity: Nova EYE Medical Ltd has 11.08% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Nova EYE Medical Ltd Industry Peers by Asset Resilience Ratio
Compare Nova EYE Medical Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Vitrolife AB
ST:VITR |
Medical Devices | 7.27% |
|
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033 |
Medical Devices | 19.31% |
|
Tellgen Corp
SHE:300642 |
Medical Devices | 8.60% |
|
Lumos Diagnostics Holdings Ltd
AU:LDX |
Medical Devices | 9.40% |
|
T&R Biofab Co. Ltd
KQ:246710 |
Medical Devices | 0.12% |
|
Ok Biotech Co Ltd
TW:4155 |
Medical Devices | 0.32% |
|
Promimic AB
ST:PRO |
Medical Devices | 8.62% |
|
Memphasys Ltd
AU:MEM |
Medical Devices | 0.00% |
Annual Asset Resilience Ratio for Nova EYE Medical Ltd (2001–2025)
The table below shows the annual Asset Resilience Ratio data for Nova EYE Medical Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 19.07% | AU$5.05 Million ≈ $3.58 Million |
AU$26.50 Million ≈ $18.75 Million |
-1.51pp |
| 2024-06-30 | 20.58% | AU$6.15 Million ≈ $4.35 Million |
AU$29.88 Million ≈ $21.14 Million |
-3.85pp |
| 2023-06-30 | 24.44% | AU$7.42 Million ≈ $5.25 Million |
AU$30.36 Million ≈ $21.48 Million |
+2.60pp |
| 2022-06-30 | 21.84% | AU$8.00 Million ≈ $5.66 Million |
AU$36.62 Million ≈ $25.91 Million |
-20.55pp |
| 2021-06-30 | 42.39% | AU$17.80 Million ≈ $12.60 Million |
AU$41.99 Million ≈ $29.71 Million |
-39.54pp |
| 2020-06-30 | 81.93% | AU$95.65 Million ≈ $67.68 Million |
AU$116.74 Million ≈ $82.60 Million |
+66.54pp |
| 2019-06-30 | 15.39% | AU$15.37 Million ≈ $10.88 Million |
AU$99.89 Million ≈ $70.68 Million |
-6.91pp |
| 2018-06-30 | 22.29% | AU$23.07 Million ≈ $16.32 Million |
AU$103.47 Million ≈ $73.21 Million |
+11.61pp |
| 2017-06-30 | 10.68% | AU$9.24 Million ≈ $6.54 Million |
AU$86.54 Million ≈ $61.23 Million |
+10.30pp |
| 2008-06-30 | 0.38% | AU$275.00K ≈ $194.58K |
AU$71.94 Million ≈ $50.90 Million |
+0.12pp |
| 2007-06-30 | 0.26% | AU$167.00K ≈ $118.16K |
AU$63.69 Million ≈ $45.06 Million |
+0.16pp |
| 2006-06-30 | 0.10% | AU$46.00K ≈ $32.55K |
AU$46.48 Million ≈ $32.88 Million |
-42.45pp |
| 2001-06-30 | 42.54% | AU$487.42K ≈ $344.88K |
AU$1.15 Million ≈ $810.63K |
-- |
About Nova EYE Medical Ltd
Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. It also engaged in the commercialisation of the subthreshold nano-pulse ophthalmic laser; 2RT, a proprietary laser technology to treat patients in early and intermediate age-related macular degen… Read more